… A database on osteogenesis imperfecta variants indicates that more than 1500 unique
COL1A1 and COL1A2 (combined) DNA variants were reported as of October 2017 (www.le.ac.uk/…

… ing the importance of generating therapeutic strategies that are independent of specific
mutations. Thus, in the current study, a mutation-independent strategy for suppression of mutant …

… Osteogenesis imperfecta (OI) is a genetic disorder that is usually caused by disturbed
production of collagen type I. Depending on its severity in the patient, this disorder may create …

… Animal models of OI and advances in the understanding of the Wnt pathway may lead to
the development of new therapeutic strategies. Gene therapy may also permit silencing of …

… Osteogenesis imperfecta (OI) is an inherited skeletal dysplasia characterized by bone
fragility and skeletal deformities. While the majority of cases are associated with pathogenic …

… X-ray of a patient with a severe form of osteogenesis imperfecta. … therapy for osteogenesis
imperfecta. Abstract presented at the 8th International Conference of Osteogenesis Imperfecta…

… In this article, we review recent data concerning pharmacologic therapy for osteogenesis
imperfecta. We searched MEDLINE from 2000 to 2005 as well as the abstract books of …

… These therapeutic strategies involve a multidisciplinary approach, encompassing bone-modifying
agents, muscle strengthening, exercise rehabilitation, as well as orthopedic …

… to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray
absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004;34:539–546. …

… Traditionally, much emphasis has been laid on the presence or absence of blue sclera and
dentinogenesis imperfecta as diagnostic signs of osteogenesis imperfecta. This practice still …